Journal
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
Volume 284, Issue 3, Pages R725-R733Publisher
AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajpregu.00326.2002
Keywords
blood pressure; D-Asp(1)angiotensin II; D-Arg(1)angiotensin III
Categories
Ask authors/readers for more resources
The present investigation measured the relative pressor potencies of intracerebroventricularly infused ANG II, ANG III, and the metabolically resistant analogs D-Asp(1) ANG II and D-Arg(1) ANG III in alert freely moving rats. The stability of these analogs was further facilitated by pretreatment with the specific aminopeptidase A inhibitor EC33 or the aminopeptidase N inhibitor PC18. The results indicate that the maximum elevations in mean arterial pressure (MAP) were very similar for each of these compounds across the dose range 1, 10, and 100 pmol/min during a 5-min infusion period. However, D-Asp(1)ANG II revealed significantly extended durations of pressor effects before return to base level MAP. Pretreatment intracerebroventricular infusion with EC33 blocked the pressor activity induced by the subsequent infusion of D-Asp(1) ANG II, whereas EC33 had no effect on the pressor response to subsequent infusion of D-Arg(1) ANG III. In contrast, pretreatment infusion with PC18 extended the duration of the D-Asp(1) ANG II pressor effect by about two to three times and the duration of D-Arg(1) ANG III's effect by similar to10 to 15 times. Pretreatment with the specific AT(1) receptor antagonist losartan blocked the pressor responses induced by the subsequent infusion of both analogs indicating that they act via the AT(1) receptor subtype. These results suggest that the brain AT(1) receptor may be designed to preferentially respond to ANG III, and ANG III's importance as a centrally active ligand has been underestimated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available